


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:51:49Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405153" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405153</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>interdiscardio</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Interdiscip Cardiovasc Thorac Surg</journal-id><journal-id journal-id-type="iso-abbrev">Interdiscip Cardiovasc Thorac Surg</journal-id><journal-id journal-id-type="pmc-domain-id">4375</journal-id><journal-id journal-id-type="pmc-domain">interdiscardio</journal-id><journal-id journal-id-type="publisher-id">icvts</journal-id><journal-title-group><journal-title>Interdisciplinary Cardiovascular and Thoracic Surgery</journal-title></journal-title-group><issn pub-type="epub">2753-670X</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405153</article-id><article-id pub-id-type="pmcid-ver">PMC12405153.1</article-id><article-id pub-id-type="pmcaid">12405153</article-id><article-id pub-id-type="pmcaiid">12405153</article-id><article-id pub-id-type="pmid">40828897</article-id><article-id pub-id-type="doi">10.1093/icvts/ivaf197</article-id><article-id pub-id-type="publisher-id">ivaf197</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Cardiac Arrhythmia</subject><subj-group subj-group-type="category-toc-heading"><subject>Original Article</subject></subj-group></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>Eacts/110</subject><subject>Eacts/103</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00920</subject></subj-group></article-categories><title-group><article-title>Hybrid Atrial Fibrillation Ablation: Association of Clinical Characteristics, Biomarkers, and Blanking Period with Recurrence</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2492-844X</contrib-id><name name-style="western"><surname>Velt</surname><given-names initials="MJH">Marieke J H</given-names></name><aff>
<institution>Department of Cardiology, Thoraxcenter, University of Groningen, University Medical Center Groningen</institution>, Groningen, 9700VB, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Magni</surname><given-names initials="FT">Federico T</given-names></name><aff>
<institution>Department of Cardiology, Thoraxcenter, University of Groningen, University Medical Center Groningen</institution>, Groningen, 9700VB, <country country="NL">The Netherlands</country></aff><aff>
<institution>Department of Cardio-Thoracic Surgery, University Medical Center Groningen</institution>, Groningen, 9700VB, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Blaauw</surname><given-names initials="Y">Yuri</given-names></name><aff>
<institution>Department of Cardiology, Thoraxcenter, University of Groningen, University Medical Center Groningen</institution>, Groningen, 9700VB, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mariani</surname><given-names initials="MA">Massimo A</given-names></name><aff>
<institution>Department of Cardio-Thoracic Surgery, University Medical Center Groningen</institution>, Groningen, 9700VB, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Klinkenberg</surname><given-names initials="TJ">Theo J</given-names></name><aff>
<institution>Department of Cardio-Thoracic Surgery, University Medical Center Groningen</institution>, Groningen, 9700VB, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2581-070X</contrib-id><name name-style="western"><surname>Rienstra</surname><given-names initials="M">Michiel</given-names></name><aff>
<institution>Department of Cardiology, Thoraxcenter, University of Groningen, University Medical Center Groningen</institution>, Groningen, 9700VB, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4411-3918</contrib-id><name name-style="western"><surname>Mulder</surname><given-names initials="BA">Bart A</given-names></name><xref rid="ivaf197-cor1" ref-type="corresp"/><aff>
<institution>Department of Cardiology, Thoraxcenter, University of Groningen, University Medical Center Groningen</institution>, Groningen, 9700VB, <country country="NL">The Netherlands</country></aff></contrib></contrib-group><author-notes><corresp id="ivaf197-cor1">Corresponding author. Department of Cardiology, Thoraxcenter, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9700 VB, Groningen, The Netherlands (<email>b.a.mulder@umcg.nl</email>)</corresp></author-notes><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-08-19"><day>19</day><month>8</month><year>2025</year></pub-date><volume>40</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">495998</issue-id><elocation-id>ivaf197</elocation-id><history><date date-type="received"><day>24</day><month>4</month><year>2025</year></date><date date-type="rev-recd"><day>29</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>18</day><month>8</month><year>2025</year></date><date date-type="corrected-typeset"><day>02</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>19</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site&#8212;for further information please contact journals.permissions@oup.com.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="ivaf197.pdf"/><self-uri xlink:href="ivaf197.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Objectives</title><p>Hybrid atrial fibrillation (AF) ablation is a treatment for therapy-resistant, symptomatic AF. Limited data exist on the risk factors for failure of the procedure. Therefore, this study aimed to identify clinical factors and blood biomarkers associated with atrial arrhythmia recurrence within 2 years following hybrid ablation.</p></sec><sec id="s2"><title>Methods</title><p>The hybrid AF ablation study is a single-centre, prospective, observational study including consecutive AF patients who underwent hybrid ablation between January 2015 and September 2021. Blood samples were collected pre-ablation, and 7 biomarkers were assessed based on their possible association with recurrence. The blanking period was defined as the first 3 months after ablation. Clinical follow-up visits combined with 12-lead electrocardiogram (ECG) and 72-hour Holter monitoring were scheduled at 3, 6, 12, and 24 months post-procedure. Cox proportional hazard regression analyses were performed to assess the association with recurrence.</p></sec><sec id="s3"><title>Results</title><p>Of the 91 patients included (mean age 57.1 years [standard deviation: 8.1]; 16% women), 31 (34%) experienced atrial arrhythmia recurrence within 2 years following hybrid ablation, with a median time to recurrence of 254 days (interquartile range 147-428). Multivariable Cox proportional hazard regression, adjusted for age and sex, showed that recurrence in the blanking period was associated with atrial arrhythmia recurrence within 2 years post-ablation (hazard ratio 4.05, 95% confidence interval 1.85-8.91); however, no association was detected between other clinical factors or blood biomarkers and atrial arrhythmia recurrence.</p></sec><sec id="s4"><title>Conclusions</title><p>In AF patients undergoing hybrid ablation, recurrence in the blanking period was associated with atrial arrhythmia recurrence within 2 years post-ablation.</p></sec><sec id="s5"><title>Clinical Registration</title><p>ClinicalTrials.gov, <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02516033">NCT02516033</ext-link>, <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT02516033" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT02516033</ext-link>.</p></sec></abstract><abstract abstract-type="teaser"><p>Hybrid atrial fibrillation (AF) ablation, a treatment for therapy-resistant, symptomatic AF patients, combines endocardial catheter and epicardial surgical ablation to leverage the strengths of both approaches and has been shown to be more effective than catheter ablation alone in patients with non-paroxysmal AF.</p></abstract><abstract abstract-type="graphical"><title>Graphical abstract</title><p>
<fig position="float" id="ivaf197-F4" orientation="portrait"><graphic position="float" orientation="portrait" xlink:href="ivaf197f4.jpg"/></fig>
</p></abstract><kwd-group><kwd>atrial fibrillation</kwd><kwd>hybrid ablation</kwd><kwd>recurrence</kwd><kwd>blanking period</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>AtriCure</institution><institution-id institution-id-type="DOI">10.13039/100007330</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><page-count count="8"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Hybrid atrial fibrillation (AF) ablation, a treatment for therapy-resistant, symptomatic AF patients, combines endocardial catheter and epicardial surgical ablation to leverage the strengths of both approaches and has been shown to be more effective than catheter ablation alone in patients with non-paroxysmal AF.<xref rid="ivaf197-B1" ref-type="bibr"><sup>1&#8211;3</sup></xref> Although several risk factors have been identified for atrial arrhythmia recurrence after catheter ablation, including comorbidities, echocardiographic values, and laboratory measurements,<xref rid="ivaf197-B4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="ivaf197-B5" ref-type="bibr"><sup>5</sup></xref> the available information regarding hybrid ablation is limited, particularly when it comes to biomarkers. Therefore, this study aimed to identify clinical factors and blood biomarkers associated with atrial arrhythmia recurrence within 2 years following single-stage hybrid ablation.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Study population</title><p>The hybrid AF ablation study (ClinicalTrials.gov, <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02516033">NCT02516033</ext-link>, <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT02516033" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT02516033</ext-link>) is a single-centre, prospective, observational study which included consecutive patients undergoing single-stage hybrid ablation between January 2015 and September 2021 at the University Medical Center Groningen (UMCG). Patients were eligible in case of symptomatic persistent or long-standing persistent AF, or paroxysmal AF with &#8805;2 failed catheter ablations. AF classification was determined using Holter monitoring and patients&#8217; medical histories, including any previous electrical or chemical cardioversion. We included patients with paroxysmal AF in our analysis to reflect the real-world heterogeneity of the patient population undergoing hybrid ablation. Exclusion criteria were a history of cardiac surgery or a body mass index &#8805;35 kg/m<sup>2</sup>. This study was approved and monitored by the institutional medical Ethics Committee (METc2014/239). Written informed consent was obtained from all patients. Collection and storage of data from research participants for multiple and indefinite use is consistent with requirements outlined in the WMA Declaration of Taipei.</p></sec><sec><title>Hybrid ablation procedure</title><p>The hybrid ablation procedure has been described previously.<xref rid="ivaf197-B6" ref-type="bibr"><sup>6</sup></xref> In brief, the right pulmonary veins (PVs) and superior caval vein (SVC) were ablated using a bipolar clamp (Isolator Synergy Clamps, AtriCure). The inclusion of an SVC lesion (not performed as a bicaval line) was aimed at eliminating potential AF triggers. Roof and inferior lines for the creation of a posterior box were created using a linear ablation device (Coolrail; AtriCure Inc.). Subsequently, ablation was carried out through a similar left thoracoscopic approach. The left PVs were isolated using the clamp and the previously created linear lines for the formation of a posterior box were connected with the left PV line. Surgical exclusion of the left atrial appendage (LAA) with a minimally invasive occlusion device (AtriClip, AtriCure) was performed only in patients with CHA2DS2-VASc score of &#8805;2, in accordance with ESC recommendations Additionally, in cases of procedural failure, no stand-alone procedure was performed to eliminate the role of the LAA.</p><p>Following the surgical procedure, the left atrium (LA) was accessed via the femoral vein with a single transseptal puncture. To create a high-density 3-dimensional electroanatomical map of the LA, a circular multipolar catheter was utilized in conjunction with NavX Ensite Velocity mapping system (NavX, St Jude Medical). Additional ablation using the TactiCath SE ablation catheter (Abbott, Chicago, IL, USA) was performed if the PVs were not isolated, surgical lines were incomplete or AF/atrial flutter (AFL)/atrial tachycardia (AT) persisted. A cavotricuspid isthmus (CTI) line was created and tested for bidirectional block in all patients. The CTI line was created to prevent CTI-dependent AFL.</p><p>Antiarrhythmic drugs were continued for the first 3 months post-procedure and discontinued in symptom-free patients thereafter. All patients were on acenocoumarol for at least 4 weeks prior to the procedure, maintaining a target INR of 2-2.5 peri-procedurally and for at least 3 months post-procedure. Oral anticoagulants were resumed based on the CHA2DS2-VASc score, regardless of LAA exclusion. A repeat ablation was performed in case of symptomatic recurrence within 3 years.</p></sec><sec><title>Follow-up</title><p>All patients were assessed at baseline for clinical history, physical examination, current medication use, blood samples, electrocardiogram (ECG), 24-hour Holter monitoring, and an echocardiogram. Outpatient clinic visits, including ECG recording, were scheduled at 1, 3, 6, 12, and 24 months post-procedure. Additionally, 72-hour Holter monitoring was conducted at 3, 6, 12, and 24 months. For the purpose of this study, we used data until the 2-year follow-up moment.</p></sec><sec><title>Biomarker analysis</title><p>Baseline blood samples were collected and EDTA plasma was analysed by Roche Diagnostics. Seven biomarkers were selected based on their possible association with AF<xref rid="ivaf197-B7" ref-type="bibr"><sup>7</sup></xref>: bone morphogenetic protein 10 (BMP10), angiopoietin-2 (ANG2), Dickkopf WNT signalling pathway inhibitor 3 (DKK3), endothelial cell-specific molecule 1 (ESM1), fibroblast growth factor 23 (FGF23), insulin-like growth factor binding protein 7 (IGFBP7), and NT-proBNP.</p></sec><sec><title>Study outcome</title><p>Recurrence was defined as any episode of AF, AFL, or AT lasting more than 30 seconds on Holter monitoring, or any episode of AF or AFL documented throughout the entire duration of a 12-lead ECG. The blanking period was defined as the first 3 months after ablation.</p></sec><sec><title>Statistical analysis</title><p>Continuous variables are presented as mean with standard deviation (SD) if normally distributed, and as median with interquartile range (IQR) (25th centile, 75th centile) if not. The normality of the data was assessed using visual inspection of histograms and Q-Q plots. Categorical variables are presented as counts with percentages. We performed univariable Cox proportional hazards regression to study the association with atrial arrhythmia recurrence. Variables yielding a <italic toggle="yes">P</italic>-value &lt;0.25 were included in the multivariable model, adjusted for age and sex. A backward stepwise approach was applied. To ensure normality of the data, biomarkers were log transformed. Hazard ratios (HRs) are presented with a 95% confidence interval (CI). The proportional hazards assumption was tested by including a time-dependent variable in the model to assess whether the HRs remained constant over time. No violations of this assumption were detected. To correct for multiple testing in univariable Cox analyses, we applied the Bonferroni correction, setting significance at <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.0014. Kaplan-Meier curves were generated to illustrate the cumulative incidence of recurrence over the follow-up period and the log-rank test was used to compare groups. Given the relatively recent recommendations regarding the blanking period, we applied a 3-month blanking period for the primary analysis and conducted a sensitivity analysis using an 8-week interval. Sample size and power calculations were not conducted, as the data come from an existing registry. All statistical analyses were conducted using IBM SPSS Statistics for Windows, version 28.0 (IBM Corp., Armonk, NY) and R software, version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria). Two-sided <italic toggle="yes">P</italic>-values &lt;0.05 were considered statistically significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Study population</title><p>From January 2015 to September 2021, 139 patients underwent hybrid ablation at the UMCG and were enrolled in the registry. For the purpose of the current study, only those with available baseline blood samples were included in the analysis (<italic toggle="yes">n</italic>&#8201;=&#8201;96). Five patients were excluded from the present analysis because the hybrid ablation was incomplete. In 2 cases, thoracic adhesions obstructed thoracoscopic access, allowing only endocardial ablation. In the other 3 patients, major bleeding during epicardial ablation rendered it unsafe to continue with endocardial ablation. Therefore, the final study population consisted of 91 patients (<bold><xref rid="ivaf197-F1" ref-type="fig">Figure&#160;1</xref></bold>). The mean age was 57.1 (SD: 8.1) years, and 15 (16%) patients were women. Among these, 12 (13%) patients were classified as having paroxysmal AF, 61 (67%) persistent AF, and 18 (20%) long-standing persistent AF. Time since first diagnosis of AF was 56 months (IQR 25-103). Thirty-eight (42%) patients had hypertension, 8 (9%) diabetes mellitus, 8 (9%) heart failure, and 6 (7%) coronary artery disease. Mortality during follow-up was low, with a single death reported among 91 patients. <bold><xref rid="ivaf197-T1" ref-type="table">Table&#160;1</xref></bold> shows the baseline characteristics of the study population.</p><fig position="float" id="ivaf197-F1" orientation="portrait"><label>Figure 1.</label><caption><p>Patient Flow Diagram</p></caption><graphic position="float" orientation="portrait" xlink:href="ivaf197f1.jpg"/></fig><table-wrap position="float" id="ivaf197-T1" orientation="portrait"><label>Table 1.</label><caption><p>Baseline Characteristics by Hybrid Ablation Procedure Outcome at 2 Years</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><td rowspan="1" colspan="1"/><th rowspan="1" colspan="1">All (<italic toggle="yes">n</italic>&#8201;=&#8201;78)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (years), mean (SD)</td><td rowspan="1" colspan="1">57.1 (8.1)</td></tr><tr><td rowspan="1" colspan="1">Female gender, counts (%)</td><td rowspan="1" colspan="1">15 (16%)</td></tr><tr><td rowspan="1" colspan="1">Type of AF, counts (%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Paroxysmal</td><td rowspan="1" colspan="1">12 (13%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Persistent</td><td rowspan="1" colspan="1">61 (67%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Long-standing persistent</td><td rowspan="1" colspan="1">18 (20%)</td></tr><tr><td rowspan="1" colspan="1">Time since first AF diagnosis (months), median (IQR)</td><td rowspan="1" colspan="1">56 [25-103]</td></tr><tr><td rowspan="1" colspan="1">Hypertension, counts (%)</td><td rowspan="1" colspan="1">38 (42%)</td></tr><tr><td rowspan="1" colspan="1">Hypercholesterolaemia, counts (%)</td><td rowspan="1" colspan="1">18 (20%)</td></tr><tr><td rowspan="1" colspan="1">Diabetes mellitus, counts (%)</td><td rowspan="1" colspan="1">8 (9%)</td></tr><tr><td rowspan="1" colspan="1">Heart failure, counts (%)</td><td rowspan="1" colspan="1">8 (9%)</td></tr><tr><td rowspan="1" colspan="1">Coronary artery disease, counts (%)</td><td rowspan="1" colspan="1">6 (7%)</td></tr><tr><td rowspan="1" colspan="1">Prior stroke, TIA or thromboembolism, counts (%)</td><td rowspan="1" colspan="1">6 (7%)</td></tr><tr><td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>), mean (SD)</td><td rowspan="1" colspan="1">28.3 (4.2)</td></tr><tr><td rowspan="1" colspan="1">Systolic blood pressure (mmHg), mean (SD)</td><td rowspan="1" colspan="1">129 (16)</td></tr><tr><td rowspan="1" colspan="1">Diastolic blood pressure (mmHg), mean (SD)</td><td rowspan="1" colspan="1">83 (11)</td></tr><tr><td rowspan="1" colspan="1">CHA<sub>2</sub>DS<sub>2</sub>-VASc score, counts (%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;0</td><td rowspan="1" colspan="1">27 (30%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;1</td><td rowspan="1" colspan="1">40 (44%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;&#8805; 2</td><td rowspan="1" colspan="1">24 (26%)</td></tr><tr><td rowspan="1" colspan="1">EHRA classification, counts (%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;I</td><td rowspan="1" colspan="1">1 (1%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;II</td><td rowspan="1" colspan="1">47 (52%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;III</td><td rowspan="1" colspan="1">42 (46%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;IV</td><td rowspan="1" colspan="1">1 (1%)</td></tr><tr><td rowspan="1" colspan="1">Recurrence in blanking period, counts (%)</td><td rowspan="1" colspan="1">19 (21%)</td></tr><tr><td rowspan="1" colspan="1">Previous ablation, counts (%)</td><td rowspan="1" colspan="1">43 (47%)</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">Medication at baseline</italic>
</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Beta-blocker, counts (%)</td><td rowspan="1" colspan="1">45 (49%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Digoxin, counts (%)</td><td rowspan="1" colspan="1">8 (9%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Calcium channel blocker, counts (%)</td><td rowspan="1" colspan="1">29 (32%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Class I AAD, counts (%)</td><td rowspan="1" colspan="1">16 (18%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Class III AAD, counts (%)</td><td rowspan="1" colspan="1">22 (24%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;ACE-I/ARB, counts (%)</td><td rowspan="1" colspan="1">45 (49%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Diuretics, counts (%)</td><td rowspan="1" colspan="1">14 (15%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;VKA, counts (%)</td><td rowspan="1" colspan="1">59 (65%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;DOAC, counts (%)</td><td rowspan="1" colspan="1">24 (26%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Statins, counts (%)</td><td rowspan="1" colspan="1">25 (27%)</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">Echocardiographic variables</italic>
</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;LVEF (%), mean (SD)</td><td rowspan="1" colspan="1">54 (8)</td></tr><tr><td rowspan="1" colspan="1">&#8195;LAVI (mL/m<sup>2</sup>), mean (SD)</td><td rowspan="1" colspan="1">40 (12)</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">Biomarkers</italic>
</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;ANG2 (ngmL), median (IQR)</td><td rowspan="1" colspan="1">2.2 [1.6-2.8]</td></tr><tr><td rowspan="1" colspan="1">&#8195;BMP10 (ngmL), median (IQR)</td><td rowspan="1" colspan="1">2.2 [1.9-2.5]</td></tr><tr><td rowspan="1" colspan="1">&#8195;DKK3 (ngmL), median (IQR)</td><td rowspan="1" colspan="1">48.7 [41.7-58.0]</td></tr><tr><td rowspan="1" colspan="1">&#8195;ESM1 (pgmL), median (IQR)</td><td rowspan="1" colspan="1">2108 [1791-2476]</td></tr><tr><td rowspan="1" colspan="1">&#8195;FGF23 (ngmL), median (IQR)</td><td rowspan="1" colspan="1">167 [138-231]</td></tr><tr><td rowspan="1" colspan="1">&#8195;IGFBP7 (ngmL), median (IQR)</td><td rowspan="1" colspan="1">94 [84-105]</td></tr><tr><td rowspan="1" colspan="1">&#8195;Total NTproBNP (pgmL), median (IQR)</td><td rowspan="1" colspan="1">1456 [717-2235]</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>Abbreviations: AAD: antiarrhythmic drugs class; ACE-I: angiotensin converting enzyme inhibitor; AF: atrial fibrillation; ANG2: angiopoietin-2; ARB: angiotensin receptor blocker; BMI: body mass index; BMP10: bone morphogenetic protein 10; DOAC: direct oral anticoagulants; DKK3: Dickkopf WNT signalling pathway inhibitor 3; ESM1: endothelial cell specific molecule 1; FGF23: fibroblast growth factor 23; IGFBP7: insulin-like growth factor binding protein 7; LAVI: left atrial volume index; LVEF: left ventricular ejection fraction; NT-proBNP: N-terminal pro b-type natriuretic peptide; TIA: transient ischaemic attack; VKA: vitamin K antagonist.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Recurrence rate following single-stage hybrid ablation</title><p>In total, 31 out of 91 patients (34%) experienced and atrial arrhythmia recurrence during a median follow-up of 2.0 years (IQR 1.1-2.1 years), corresponding to a linearized risk of 20 per 100 patient-years. Among these, 12 (39%) patients had AF and 19 (61%) patients AFL. The median duration between ablation and recurrence was 254 days (IQR 147-428 days). Among the 13 patients who experienced recurrences both during the blanking period and later during follow-up, 6 (46%) had the same type of arrhythmia throughout (AFL in 5, AF in 1), 3 (31%) had AF episodes during the blanking period and AFL episodes during follow-up, 1 (8%) had AFL episodes during the blanking period and AF episodes during follow-up, and 3 (%) showed 1 type of recurrence during the blanking period (AFL in 2, AF in 1), but both AF and AFL during follow-up. Univariable Cox regression analysis revealed a significant association between recurrence during the blanking period and the outcome (HR 3.82, 95% CI, 1.86-7.82, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) (<bold><xref rid="ivaf197-T2" ref-type="table">Table&#160;2</xref></bold>). This association remained significant after adjustments for age and sex (HR 4.05, 95% CI, 1.85-8.91, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). No significant associations were observed between other clinical characteristics or blood biomarkers and atrial arrhythmia recurrence within 2 years after hybrid ablation. Kaplan-Meier curves illustrating outcomes based on AF type and recurrence during the blanking period are shown in <bold><xref rid="ivaf197-F2" ref-type="fig">Figures&#160;2</xref> and <xref rid="ivaf197-F3" ref-type="fig">3</xref></bold>.</p><fig position="float" id="ivaf197-F2" orientation="portrait"><label>Figure 2.</label><caption><p>Kaplan-Meier Curve of the Arrhythmia-Free Cumulative Survival Rates 2 Years After Hybrid Ablation According to Atrial Fibrillation Type. Abbreviation: AF: atrial fibrillation</p></caption><graphic position="float" orientation="portrait" xlink:href="ivaf197f2.jpg"/></fig><fig position="float" id="ivaf197-F3" orientation="portrait"><label>Figure 3.</label><caption><p>Kaplan-Meier Curve of the Arrhythmia-Free Cumulative Survival Rates 2 Years After Hybrid Ablation According to Recurrence During the Blanking Period. Abbreviation: AF: atrial fibrillation</p></caption><graphic position="float" orientation="portrait" xlink:href="ivaf197f3.jpg"/></fig><table-wrap position="float" id="ivaf197-T2" orientation="portrait"><label>Table 2.</label><caption><p>Univariable and Multivariable Cox Regression Analysis for Atrial Arrhythmia Recurrence at 2 Years Post-Ablation</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="char" char="." span="1"/><col valign="top" align="char" char="." span="1"/><col valign="top" align="char" char="." span="1"/></colgroup><thead><tr><td rowspan="1" colspan="1"/><th rowspan="1" colspan="1">HR</th><th rowspan="1" colspan="1">95% CI</th><th rowspan="1" colspan="1">
<italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Univariable analysis</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Age</td><td rowspan="1" colspan="1">1.05</td><td rowspan="1" colspan="1">1.00-1.10</td><td rowspan="1" colspan="1">0.059</td></tr><tr><td rowspan="1" colspan="1">&#8195;Female gender</td><td rowspan="1" colspan="1">1.31</td><td rowspan="1" colspan="1">0.54-3.21</td><td rowspan="1" colspan="1">0.550</td></tr><tr><td rowspan="1" colspan="1">Type of AF</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Paroxysmal</td><td rowspan="1" colspan="1">0.21</td><td rowspan="1" colspan="1">0.10-1.68</td><td rowspan="1" colspan="1">0.210</td></tr><tr><td rowspan="1" colspan="1">&#8195;Persistent</td><td rowspan="1" colspan="1">0.95</td><td rowspan="1" colspan="1">0.45-2.02</td><td rowspan="1" colspan="1">0.892</td></tr><tr><td rowspan="1" colspan="1">&#8195;Long-standing persistent</td><td rowspan="1" colspan="1">1.77</td><td rowspan="1" colspan="1">0.79-3.98</td><td rowspan="1" colspan="1">0.163</td></tr><tr><td rowspan="1" colspan="1">&#8195;Time since first AF diagnosis (months)</td><td rowspan="1" colspan="1">1.00</td><td rowspan="1" colspan="1">0.99-1.00</td><td rowspan="1" colspan="1">0.197</td></tr><tr><td rowspan="1" colspan="1">&#8195;Hypertension</td><td rowspan="1" colspan="1">1.26</td><td rowspan="1" colspan="1">0.62-2.57</td><td rowspan="1" colspan="1">0.518</td></tr><tr><td rowspan="1" colspan="1">&#8195;Hypercholesterolaemia</td><td rowspan="1" colspan="1">0.38</td><td rowspan="1" colspan="1">0.11-1.25</td><td rowspan="1" colspan="1">0.111</td></tr><tr><td rowspan="1" colspan="1">&#8195;Diabetes mellitus</td><td rowspan="1" colspan="1">0.89</td><td rowspan="1" colspan="1">0.27-2.93</td><td rowspan="1" colspan="1">0.846</td></tr><tr><td rowspan="1" colspan="1">&#8195;Heart failure</td><td rowspan="1" colspan="1">0.58</td><td rowspan="1" colspan="1">0.14-2.44</td><td rowspan="1" colspan="1">0.459</td></tr><tr><td rowspan="1" colspan="1">&#8195;Coronary artery disease</td><td rowspan="1" colspan="1">1.92</td><td rowspan="1" colspan="1">0.58-6.36</td><td rowspan="1" colspan="1">0.283</td></tr><tr><td rowspan="1" colspan="1">&#8195;Prior stroke, TIA or thromboembolism</td><td rowspan="1" colspan="1">1.65</td><td rowspan="1" colspan="1">0.50-5.43</td><td rowspan="1" colspan="1">0.413</td></tr><tr><td rowspan="1" colspan="1">&#8195;BMI (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">1.04</td><td rowspan="1" colspan="1">0.94-1.15</td><td rowspan="1" colspan="1">0.418</td></tr><tr><td rowspan="1" colspan="1">&#8195;Systolic blood pressure</td><td rowspan="1" colspan="1">1.01</td><td rowspan="1" colspan="1">0.99-1.04</td><td rowspan="1" colspan="1">0.223</td></tr><tr><td rowspan="1" colspan="1">&#8195;Diastolic blood pressure</td><td rowspan="1" colspan="1">1.02</td><td rowspan="1" colspan="1">0.99-1.05</td><td rowspan="1" colspan="1">0.176</td></tr><tr><td rowspan="1" colspan="1">&#8195;CHA<sub>2</sub>DS<sub>2</sub>-VASc score</td><td rowspan="1" colspan="1">1.09</td><td rowspan="1" colspan="1">0.85-1.40</td><td rowspan="1" colspan="1">0.479</td></tr><tr><td rowspan="1" colspan="1">&#8195;Recurrence in blanking period</td><td rowspan="1" colspan="1">3.82</td><td rowspan="1" colspan="1">1.86-7.82</td><td rowspan="1" colspan="1">&lt;0.001<xref rid="tblfn3" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td rowspan="1" colspan="1">&#8195;Previous ablation</td><td rowspan="1" colspan="1">0.71</td><td rowspan="1" colspan="1">0.34-1.47</td><td rowspan="1" colspan="1">0.359</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">Medication at baseline</italic>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Beta-blocker</td><td rowspan="1" colspan="1">1.24</td><td rowspan="1" colspan="1">0.60-2.54</td><td rowspan="1" colspan="1">0.557</td></tr><tr><td rowspan="1" colspan="1">&#8195;Digoxin</td><td rowspan="1" colspan="1">0.33</td><td rowspan="1" colspan="1">0.04-2.42</td><td rowspan="1" colspan="1">0.275</td></tr><tr><td rowspan="1" colspan="1">&#8195;Calcium channel blocker</td><td rowspan="1" colspan="1">1.32</td><td rowspan="1" colspan="1">0.63-2.76</td><td rowspan="1" colspan="1">0.459</td></tr><tr><td rowspan="1" colspan="1">&#8195;Class I AAD</td><td rowspan="1" colspan="1">0.70</td><td rowspan="1" colspan="1">0.24-2.01</td><td rowspan="1" colspan="1">0.506</td></tr><tr><td rowspan="1" colspan="1">&#8195;Class III AAD</td><td rowspan="1" colspan="1">1.20</td><td rowspan="1" colspan="1">0.55-2.60</td><td rowspan="1" colspan="1">0.653</td></tr><tr><td rowspan="1" colspan="1">&#8195;ACE-I/ARB</td><td rowspan="1" colspan="1">1.04</td><td rowspan="1" colspan="1">0.52-2.11</td><td rowspan="1" colspan="1">0.903</td></tr><tr><td rowspan="1" colspan="1">&#8195;Diuretics</td><td rowspan="1" colspan="1">1.13</td><td rowspan="1" colspan="1">0.43-2.96</td><td rowspan="1" colspan="1">0.798</td></tr><tr><td rowspan="1" colspan="1">&#8195;VKA</td><td rowspan="1" colspan="1">1.14</td><td rowspan="1" colspan="1">0.55-2.39</td><td rowspan="1" colspan="1">0.727</td></tr><tr><td rowspan="1" colspan="1">&#8195;DOAC</td><td rowspan="1" colspan="1">1.15</td><td rowspan="1" colspan="1">0.53-2.49</td><td rowspan="1" colspan="1">0.732</td></tr><tr><td rowspan="1" colspan="1">&#8195;Statins</td><td rowspan="1" colspan="1">1.02</td><td rowspan="1" colspan="1">0.45-2.30</td><td rowspan="1" colspan="1">0.956</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">Echocardiographic variables</italic>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;LVEF (%)</td><td rowspan="1" colspan="1">1.01</td><td rowspan="1" colspan="1">0.96-1.06</td><td rowspan="1" colspan="1">0.840</td></tr><tr><td rowspan="1" colspan="1">&#8195;LAVI (mL/m<sup>2</sup>)</td><td rowspan="1" colspan="1">1.02</td><td rowspan="1" colspan="1">0.99-1.05</td><td rowspan="1" colspan="1">0.173</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">Biomarkers</italic>
<xref rid="tblfn4" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;ANG2 (ngmL)</td><td rowspan="1" colspan="1">0.95</td><td rowspan="1" colspan="1">0.48-1.89</td><td rowspan="1" colspan="1">0.889</td></tr><tr><td rowspan="1" colspan="1">&#8195;BMP10 (ngmL)</td><td rowspan="1" colspan="1">1.29</td><td rowspan="1" colspan="1">0.26-6.38</td><td rowspan="1" colspan="1">0.755</td></tr><tr><td rowspan="1" colspan="1">&#8195;DKK3 (ngmL)</td><td rowspan="1" colspan="1">2.38</td><td rowspan="1" colspan="1">0.54-10.53</td><td rowspan="1" colspan="1">0.253</td></tr><tr><td rowspan="1" colspan="1">&#8195;ESM1 (pgmL)</td><td rowspan="1" colspan="1">1.08</td><td rowspan="1" colspan="1">0.32-3.67</td><td rowspan="1" colspan="1">0.899</td></tr><tr><td rowspan="1" colspan="1">&#8195;FGF23 (ngmL)</td><td rowspan="1" colspan="1">0.94</td><td rowspan="1" colspan="1">0.46-1.94</td><td rowspan="1" colspan="1">0.871</td></tr><tr><td rowspan="1" colspan="1">&#8195;IGFBP7 (ngmL)</td><td rowspan="1" colspan="1">3.39</td><td rowspan="1" colspan="1">0.56-20.40</td><td rowspan="1" colspan="1">0.182</td></tr><tr><td rowspan="1" colspan="1">&#8195;Total NTproBNP (pgmL)</td><td rowspan="1" colspan="1">1.32</td><td rowspan="1" colspan="1">0.89-1.94</td><td rowspan="1" colspan="1">0.165</td></tr><tr><td rowspan="1" colspan="1">Multivariable analysis</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Age</td><td rowspan="1" colspan="1">1.03</td><td rowspan="1" colspan="1">0.98-1.09</td><td rowspan="1" colspan="1">0.248</td></tr><tr><td rowspan="1" colspan="1">&#8195;Female</td><td rowspan="1" colspan="1">1.68</td><td rowspan="1" colspan="1">0.60-4.68</td><td rowspan="1" colspan="1">0.321</td></tr><tr><td rowspan="1" colspan="1">&#8195;Recurrence in blanking period</td><td rowspan="1" colspan="1">4.05</td><td rowspan="1" colspan="1">1.85-8.91</td><td rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn id="tblfn2"><p>Abbreviations: AAD: antiarrhythmic drugs class; ACE-I: angiotensin converting enzyme inhibitor; AF: atrial fibrillation; ANG2: angiopoietin-2; ARB: angiotensin receptor blocker; BMI: body mass index; BMP10: bone morphogenetic protein 10; DKK3: Dickkopf WNT signalling pathway inhibitor 3; DOAC: direct oral anticoagulants; ESM1: endothelial cell specific molecule 1; FGF23: fibroblast growth factor 23; IGFBP7: insulin-like growth factor binding protein 7; LAVI: left atrial volume index; LVEF: left ventricular ejection fraction; NT-proBNP: N-terminal pro b-type natriuretic peptide; TIA: transient ischaemic attack; VKA: vitamin K antagonist.</p></fn><fn id="tblfn3"><label>a</label><p>Log-transformed.</p></fn><fn id="tblfn4"><label>b</label><p>
<italic toggle="yes">P</italic>-value significant after Bonferroni correction.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Sensitivity analysis</title><p>Given the recent adjustment of the blanking period to 8 weeks, we conducted a sensitivity analysis to validate the robustness of our primary findings. In this sensitivity analysis, we evaluated the association between recurrence within an 8-week blanking period and recurrence at 2 years following hybrid ablation. Our results remained consistent, showing similar associations between a recurrence in the 8-week blanking period and subsequent recurrences during 2 years follow-up (HR 3.61, 95% CI, 1.69-7.74, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001).</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The aim of this study was to investigate the association between clinical factors and blood biomarkers with atrial arrhythmia recurrence within 2 years following hybrid ablation. Our findings demonstrate a 66% recurrence-free survival rate at 2 years post-ablation. This is comparable with reported outcomes after hybrid ablation in the CEASE-AF trial.<xref rid="ivaf197-B8" ref-type="bibr"><sup>8</sup></xref> Furthermore, our findings suggest that recurrence during the blanking period, whether it is 8 weeks or 3 months, is the most critical factor associated with late recurrence post-ablation. No associations were observed between any of the baseline clinical factors and measured blood biomarkers with atrial arrhythmia recurrence.</p><sec><title>Characteristics of recurrence</title><p>In the present study, most patients experienced initial recurrence within 1 year following ablation (median 254 days [IQR 146-428]). This highlights the need for close follow-up during this critical period, aligning with current practice of visits at 1, 3, 6, 12, and 24 months post-ablation. Furthermore, we observed that over half of all recurrences (61%) following the ablation involved AFL. This observation aligns with the findings of Kress et al<xref rid="ivaf197-B9" ref-type="bibr"><sup>9</sup></xref> (2020), who found that 53% of recurrence encompasses AFL. They also reported that perimitral involvement was observed in 50% of AFL recurrences in their study.<xref rid="ivaf197-B9" ref-type="bibr"><sup>9</sup></xref> This finding indicates the difficulty in ablating the mitral isthmus and highlights the need to confirm conduction block. Notably, in single-staged hybrid ablation, presence of tissue oedema may influence endocardial mapping and thereby limit the formation of durable transmural lesions in the long term.<xref rid="ivaf197-B10" ref-type="bibr"><sup>10</sup></xref> Furthermore, our findings also revealed that 46% of patients who experienced a recurrence during the blanking period had the same type of recurrence at a later stage. In cases where there was a change in the recurrence type, the most common pattern observed was the presence of AF during the blanking period, which was subsequently followed by AFL during the follow-up period.</p></sec><sec><title>Risk factors for atrial arrhythmia recurrence</title><p>Previous studies often point to age and comorbidities as significant risk factors for atrial arrhythmia recurrence following catheter ablation.<xref rid="ivaf197-B4" ref-type="bibr"><sup>4</sup></xref> Furthermore, it is well established that sinus rhythm maintenance after catheter ablation for persistent AF is less successful compared to paroxysmal AF.<xref rid="ivaf197-B4" ref-type="bibr"><sup>4</sup></xref> This is thought to be due to extensive electrical and structural remodelling and frequently found non-PV triggers in patients with non-paroxysmal AF.<xref rid="ivaf197-B11" ref-type="bibr"><sup>11</sup></xref> This complexity may pose challenges in achieving complete and long-lasting ablation. Our results, however, did not show that any of the commonly identified risk factors for recurrence after catheter ablation were relevant in this patient population. These results align with those of Pannone et al<xref rid="ivaf197-B12" ref-type="bibr"><sup>12</sup></xref> (2023), who only identified left atrial volume index and recurrence during the blanking period as independent predictors of recurrence after hybrid ablation. They found no significant association between age, comorbidities, and type of AF with recurrence.<xref rid="ivaf197-B12" ref-type="bibr"><sup>12</sup></xref> However, it is important to consider that the small sample may have lacked the statistical power to reveal associations usually reported in similar research.</p><p>In contrast to research findings in radiofrequency and cryoballoon ablation,<xref rid="ivaf197-B5" ref-type="bibr"><sup>5</sup></xref> we did not observe significant associations between blood biomarkers and atrial arrhythmia recurrence after hybrid ablation. While the limited sample size may have reduced statistical power, the biomarker selection could also explain the lack of association. Although selected for their relevance to distinct pathophysiological processes in AF via a modified Delphi process within the CATCH ME consortium,<xref rid="ivaf197-B13" ref-type="bibr"><sup>13</sup></xref> it remains possible that other biomarkers have stronger associations with the outcome of interest.</p></sec><sec><title>Blanking period</title><p>The blanking period, defined as a 3-month interval following any form of myocardial ablation, is traditionally excluded from reporting procedural outcomes.<xref rid="ivaf197-B14" ref-type="bibr"><sup>14</sup></xref> However, new recommendations indicate the use of an 8-week blanking period after AF ablation in future clinical trial designs.<xref rid="ivaf197-B4" ref-type="bibr"><sup>4</sup></xref> This decision is based upon multiple studies indicating that recurrences during the blanking period were predictive for freedom of recurrence later on.<xref rid="ivaf197-B15" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="ivaf197-B16" ref-type="bibr"><sup>16</sup></xref> Furthermore, recurrence at the end of the 3-month blanking period was associated with a higher likelihood of later recurrence compared to recurrence early in the blanking period.<xref rid="ivaf197-B17" ref-type="bibr"><sup>17</sup></xref></p><p>In line with previous research findings,<xref rid="ivaf197-B18" ref-type="bibr"><sup>18</sup></xref><sup>,</sup><xref rid="ivaf197-B19" ref-type="bibr"><sup>19</sup></xref> our study demonstrates that atrial arrhythmia recurrences during the blanking period are linked to subsequent recurrences later on. This association persisted even after adjusting for age and sex in the Cox regression analysis. Besides, a sensitivity analysis with an 8-week blanking period instead of a 3-month blanking period exhibited comparable results. The exact mechanisms underlying recurrence during the blanking period are not fully understood, but prior studies suggest that incomplete PV isolation and non-PV triggers may be among the contributing factors.<xref rid="ivaf197-B20" ref-type="bibr"><sup>20</sup></xref> Recurrence during the blanking period may therefore indicate the presence of a substrate that is more difficult to ablate and therefore increase the risk of recurrences later on. One may question whether recurrence during the blanking period is a true risk factor for later recurrence or simply an intermediate marker. It is likely that the same factors driving early recurrence also contribute to late recurrence. Future studies are needed to clarify this relationship.</p><p>Although this finding cannot guide patient selection for the hybrid AF procedure, it provides prognostic insights. Early recurrence after hybrid ablation appears to correlate with an increased risk of subsequent arrhythmic episodes. It should be noted that recurrence may not be detected in some patients during the blanking period, since antiarrhythmic drugs are used for up to 3 months post-procedure and might mask recurrences in the early stages.</p></sec><sec><title>Limitations</title><p>There are several limitations that need consideration. Due to the small sample size and selective patient population, the statistical power to detect significant associations is limited, which may account for the absence of commonly associated recurrence factors. Furthermore, it is plausible that we may have overlooked some asymptomatic recurrence of atrial arrhythmias, as we did not conduct continuous heart rhythm monitoring. Also, there was no structured follow-up conducted after a 24-month period.</p></sec></sec><sec sec-type="conclusion"><title>CONCLUSION</title><p>In AF patients undergoing hybrid extensive ablation, recurrence in the blanking period was determinant of atrial arrhythmia recurrence within 2 years post-ablation. Further research is needed to better understand the mechanisms underlying atrial arrhythmia recurrence after hybrid ablation and to identify additional predictors of this outcome.</p></sec></body><back><ack id="ack1"><title>ACKNOWLEDGEMENTS</title><p>The graphical abstract was created using BioRender.com.</p></ack><sec><title>AUTHOR CONTRIBUTIONS</title><p>Conceptualization: M.J.H.V., M.R., and B.A.M.; Methodology: M.J.H.V., B.A.M.; Formal analysis: M.J.H.V.; Investigation: M.A.M., T.J.K.; Data curation: M.J.H.V., F.T.M., and Y.B.; Writing&#8212;original draft preparation: M.J.H.V.; Writing&#8212;review &amp; editing: F.T.M., Y.B., M.A.M., T.J.K., M.R., and B.A.M.; Supervision: B.A.M.; Funding acquisition: M.A.M., T.J.K.</p></sec><sec><title>FUNDING</title><p>This work was supported by a research grant from AtriCure.</p></sec><sec sec-type="COI-statement"><title>CONFLICTS OF INTEREST</title><p>Y.B. reports research grants (to department) from AtriCure and Medtronic. M.A.M. reports grants from Abbott, AtriCure, and Edwards and Consultancy from LivaNova and Medtronic. T.J.K. reports consultancy for AtriCure. M.R. reports consultancy fees from Bayer (OCEANIC-AF national PI) and InCarda Therapeutics (RESTORE-1 national PI) to the institution. M.R. reports an unrestricted research grant from the Dutch Heart Foundation and is conducted in collaboration with and supported by the Dutch CardioVascular Alliance, 01-002-2022-0118 EmbRACE. Unrestricted research grant from ZonMW and the Dutch Heart Foundation; DECISION project 848090001. Unrestricted research grants from the Netherlands Cardiovascular Research Initiative: an initiative with the support of the Dutch Heart Foundation; RACE V (CVON 2014-9), RED-CVD (CVON2017-11). Unrestricted research grant from Top Sector Life Sciences and Health to the Dutch Heart Foundation [PPP Allowance; CVON-AI (2018B017)]. M.R. reports an unrestricted grant from the European Union&#8217;s Horizon 2020 research and innovation programme under grant agreement; EHRA-PATHS (945260). M.J.H.V., F.T.M., and B.A.M. have no conflicts of interest to declare.</p></sec><sec sec-type="data-availability"><title>DATA AVAILABILITY</title><p>The data underlying this article will be shared on reasonable request to the corresponding author.</p></sec><ref-list id="ref1"><title>REFERENCES</title><ref id="ivaf197-B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Eranki</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wilson-Smith</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Flynn</surname><given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Manganas</surname><given-names>C.</given-names></string-name></person-group> &#160;<article-title>Hybrid convergent ablation versus endocardial catheter ablation for atrial fibrillation: a systematic review and meta-analysis of randomised control trials and propensity matched studies</article-title>. <source>J Cardiothorac Surg</source>. <year>2022</year>;<volume>17</volume>:<fpage>181</fpage>. <pub-id pub-id-type="doi">10.1186/S13019-022-01930-7</pub-id><pub-id pub-id-type="pmid">35964093</pub-id><pub-id pub-id-type="pmcid">PMC9375401</pub-id></mixed-citation></ref><ref id="ivaf197-B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kress</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Erickson</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Choudhuri</surname><given-names>I</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Comparative effectiveness of hybrid ablation versus endocardial catheter ablation alone in patients with persistent atrial fibrillation</article-title>. <source>JACC Clin Electrophysiol</source>. <year>2017</year>;<volume>3</volume>:<fpage>341</fpage>-<lpage>349</lpage>. <pub-id pub-id-type="doi">10.1016/J.JACEP.2016.10.010</pub-id><pub-id pub-id-type="pmid">29759446</pub-id></mixed-citation></ref><ref id="ivaf197-B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Delurgio</surname><given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>Crossen</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Gill</surname><given-names>J</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Hybrid convergent procedure for the treatment of persistent and long-standing persistent atrial fibrillation: results of CONVERGE clinical trial</article-title>. <source>Circ Arrhythm Electrophysiol</source>. <year>2020</year>;<volume>13</volume>:<fpage>E009288</fpage>. <pub-id pub-id-type="doi">10.1161/CIRCEP.120.009288</pub-id><pub-id pub-id-type="pmid">33185144</pub-id></mixed-citation></ref><ref id="ivaf197-B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tzeis</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gerstenfeld</surname><given-names>EP</given-names></string-name>, <string-name name-style="western"><surname>Kalman</surname><given-names>J</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation</article-title>. <source>J Interv Card Electrophysiol</source>. <year>2024</year>;<volume>67</volume>:<fpage>921</fpage>-<lpage>1072</lpage>. <pub-id pub-id-type="doi">10.1007/s10840-024-01771-5</pub-id><pub-id pub-id-type="pmid">38609733</pub-id></mixed-citation></ref><ref id="ivaf197-B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Boyalla</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Harling</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Snell</surname><given-names>A</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Biomarkers as predictors of recurrence of atrial fibrillation post ablation: an updated and expanded systematic review and meta-analysis</article-title>. <source>Clin Res Cardiol</source>. <year>2022</year>;<volume>111</volume>:<fpage>680</fpage>-<lpage>691</lpage>. <pub-id pub-id-type="doi">10.1007/S00392-021-01978-W</pub-id><pub-id pub-id-type="pmid">34999932</pub-id><pub-id pub-id-type="pmcid">PMC9151522</pub-id></mixed-citation></ref><ref id="ivaf197-B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Al-Jazairi</surname><given-names>MIH</given-names></string-name>, <string-name name-style="western"><surname>Rienstra</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Klinkenberg</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Mariani</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Van Gelder</surname><given-names>IC</given-names></string-name>, <string-name name-style="western"><surname>Blaauw</surname><given-names>Y.</given-names></string-name></person-group> &#160;<article-title>Hybrid atrial fibrillation ablation in patients with persistent atrial fibrillation or failed catheter ablation</article-title>. <source>Netherlands Hear J</source>. <year>2019</year>;<volume>27</volume>:<fpage>142</fpage>-<lpage>151</lpage>. <pub-id pub-id-type="doi">10.1007/S12471-019-1228-3</pub-id><pub-id pub-id-type="pmcid">PMC6393682</pub-id><pub-id pub-id-type="pmid">30715671</pub-id></mixed-citation></ref><ref id="ivaf197-B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pal&#224;</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Alejandro</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Pagola</surname><given-names>J</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Blood-based biomarkers to search for atrial fibrillation in high-risk asymptomatic individuals and cryptogenic stroke patients</article-title>. <source>Front Cardiovasc Med</source>. <year>2022</year>;<volume>9</volume>:<fpage>908053</fpage>.<pub-id pub-id-type="pmid">35859587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcvm.2022.908053</pub-id><pub-id pub-id-type="pmcid">PMC9289129</pub-id></mixed-citation></ref><ref id="ivaf197-B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Aerts</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kawczynski</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Bidar</surname><given-names>E</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Short- and long-term outcomes in isolated vs. hybrid thoracoscopic ablation in patients with atrial fibrillation: a systematic review and reconstructed individual patient data meta-analysis</article-title>. <source>Europace</source>. <year>2024</year>;<volume>26</volume>:<fpage>euae232</fpage>. <pub-id pub-id-type="doi">10.1093/EUROPACE/EUAE232</pub-id><pub-id pub-id-type="pmid">39255332</pub-id><pub-id pub-id-type="pmcid">PMC11448334</pub-id></mixed-citation></ref><ref id="ivaf197-B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kress</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Erickson</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mengesha</surname><given-names>TW</given-names></string-name>, <string-name name-style="western"><surname>Krum</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sra</surname><given-names>J.</given-names></string-name></person-group> &#160;<article-title>Characterizing recurrence following hybrid ablation in patients with persistent atrial fibrillation</article-title>. <source>J Patient-Centered Res Rev</source>. <year>2020</year>;<volume>7</volume>:<fpage>227</fpage>-<lpage>238</lpage>. <pub-id pub-id-type="doi">10.17294/2330-0698.1744</pub-id><pub-id pub-id-type="pmcid">PMC7398631</pub-id><pub-id pub-id-type="pmid">32760754</pub-id></mixed-citation></ref><ref id="ivaf197-B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bulava</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mokracek</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hanis</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kurfirst</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Eisenberger</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pesl</surname><given-names>L.</given-names></string-name></person-group> &#160;<article-title>Sequential hybrid procedure for persistent atrial fibrillation</article-title>. <source>J Am Heart Assoc</source>. <year>2015</year>;<volume>4</volume>:<fpage>e001754</fpage>. <pub-id pub-id-type="doi">10.1161/JAHA.114.001754</pub-id><pub-id pub-id-type="pmid">25809548</pub-id><pub-id pub-id-type="pmcid">PMC4392449</pub-id></mixed-citation></ref><ref id="ivaf197-B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nattel</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Harada</surname><given-names>M.</given-names></string-name></person-group> &#160;<article-title>Atrial remodeling and atrial fibrillation: recent advances and translational perspectives</article-title>. <source>J Am Coll Cardiol</source>. <year>2014</year>;<volume>63</volume>:<fpage>2335</fpage>-<lpage>2345</lpage>. <pub-id pub-id-type="doi">10.1016/J.JACC.2014.02.555</pub-id><pub-id pub-id-type="pmid">24613319</pub-id></mixed-citation></ref><ref id="ivaf197-B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pannone</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mouram</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Della Rocca</surname><given-names>DG</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Hybrid atrial fibrillation ablation: long-term outcomes from a single-centre 10-year experience</article-title>. <source>Europace</source>. <year>2023</year>;<volume>25</volume>:<fpage>1</fpage>-<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/EUROPACE/EUAD114</pub-id><pub-id pub-id-type="pmid">37246904</pub-id><pub-id pub-id-type="pmcid">PMC10226374</pub-id></mixed-citation></ref><ref id="ivaf197-B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chua</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Easter</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Guasch</surname><given-names>E</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Development and external validation of predictive models for prevalent and recurrent atrial fibrillation: a protocol for the analysis of the CATCH ME combined dataset</article-title>. <source>BMC Cardiovasc Disord</source>. <year>2019</year>;<volume>19</volume>:<fpage>120</fpage>. <pub-id pub-id-type="doi">10.1186/S12872-019-1105-4</pub-id><pub-id pub-id-type="pmid">31113362</pub-id><pub-id pub-id-type="pmcid">PMC6528378</pub-id></mixed-citation></ref><ref id="ivaf197-B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Calkins</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hindricks</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Cappato</surname><given-names>R</given-names></string-name></person-group>, Document Reviewers:, <etal>et al</etal> &#160;<article-title>2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation</article-title>. <source>Europace</source>. <year>2018</year>;<volume>20</volume>:<fpage>e1</fpage>-<lpage>e160</lpage>. <pub-id pub-id-type="doi">10.1093/EUROPACE/EUX274</pub-id><pub-id pub-id-type="pmcid">PMC5834122</pub-id><pub-id pub-id-type="pmid">29016840</pub-id></mixed-citation></ref><ref id="ivaf197-B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liang</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Elafros</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Chik</surname><given-names>WW</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Early recurrence of atrial arrhythmias following pulmonary vein antral isolation: timing and frequency of early recurrences predicts long-term ablation success</article-title>. <source>Hear Rhythm</source>. <year>2015</year>;<volume>12</volume>:<fpage>2461</fpage>-<lpage>2468</lpage>. <pub-id pub-id-type="doi">10.1016/J.HRTHM.2015.07.015</pub-id><pub-id pub-id-type="pmid">26187447</pub-id></mixed-citation></ref><ref id="ivaf197-B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Amankwah</surname><given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>Pothineni</surname><given-names>NVK</given-names></string-name>, <string-name name-style="western"><surname>Guandalini</surname><given-names>G</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Impact of atrial fibrillation recurrences during the blanking period following catheter ablation on long-term arrhythmia-free survival: a prospective study with continuous monitoring</article-title>. <source>J Interv Card Electrophysiol</source>. <year>2022</year>;<volume>65</volume>:<fpage>519</fpage>-<lpage>525</lpage>. <pub-id pub-id-type="doi">10.1007/S10840-022-01291-0</pub-id><pub-id pub-id-type="pmid">35794440</pub-id></mixed-citation></ref><ref id="ivaf197-B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Steinberg</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Champagne</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Deyell</surname><given-names>MW</given-names></string-name></person-group>, <etal>et al</etal>; <collab>CIRCA-DOSE Study Investigators</collab>. <article-title>Prevalence and outcome of early recurrence of atrial tachyarrhythmias in the cryoballoon vs irrigated radiofrequency catheter ablation (CIRCA-DOSE) study</article-title>. <source>Hear Rhythm</source>. <year>2021</year>;<volume>18</volume>:<fpage>1463</fpage>-<lpage>1470</lpage>. <pub-id pub-id-type="doi">10.1016/J.HRTHM.2021.06.1172</pub-id><pub-id pub-id-type="pmid">34126269</pub-id></mixed-citation></ref><ref id="ivaf197-B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Joshi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Kamath</surname><given-names>GS</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Prevalence, predictors, and prognosis of atrial fibrillation early after pulmonary vein isolation: findings from 3 months of continuous automatic ECG loop recordings</article-title>. <source>J Cardiovasc Electrophysiol</source>. <year>2009</year>;<volume>20</volume>:<fpage>1089</fpage>-<lpage>1094</lpage>. <pub-id pub-id-type="doi">10.1111/J.1540-8167.2009.01506.X</pub-id><pub-id pub-id-type="pmid">19549038</pub-id></mixed-citation></ref><ref id="ivaf197-B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lellouche</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ja&#239;s</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Nault</surname><given-names>I</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Early recurrences after atrial fibrillation ablation: prognostic value and effect of early reablation</article-title>. <source>J Cardiovasc Electrophysiol</source>. <year>2008</year>;<volume>19</volume>:<fpage>599</fpage>-<lpage>605</lpage>. <pub-id pub-id-type="doi">10.1111/J.1540-8167.2008.01188.X</pub-id><pub-id pub-id-type="pmid">18462321</pub-id></mixed-citation></ref><ref id="ivaf197-B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Darden</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Aldaas</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Malladi</surname><given-names>CL</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Association between early recurrences of atrial tachyarrhythmias and long-term outcomes in patients after repeat atrial fibrillation ablation</article-title>. <source>J Interv Card Electrophysiol</source>. <year>2022</year>;<volume>64</volume>:<fpage>323</fpage>-<lpage>331</lpage>. <pub-id pub-id-type="doi">10.1007/S10840-021-00987-Z</pub-id><pub-id pub-id-type="pmid">33826085</pub-id><pub-id pub-id-type="pmcid">PMC9399025</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>